Email this page: News Release
Catalyst Pharmaceutical Partners, Inc. Announces Commencement of Phase I(a) Safety Study for CPP-115
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by Catalyst Pharmaceuticals, Inc. for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps Catalyst Pharmaceuticals, Inc. prevent automated submissions.